Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

C/EBPβ Is Upregulated Through STAT5 and Accelerates Exhaustion of Leukemic Stem Cells During BCR-ABL-Mediated Myeloid Expansion

Yoshihiro Hayashi, MD, Hideyo Hirai, MD, PhD, Hisayuki Yao, MD, PhD, Satoshi Yoshioka, MD, Akihiro Tamura, MD, Yasuo Miura, MD, PhD, Eishi Ashihara, MD, PhD, Yoshihide Fujiyama, MD, PhD, Daniel G. Tenen, MD, Taira Maekawa, MD, PhD

Blood (2012) 120 (21): 907.

https://doi.org/10.1182/blood.V120.21.907.907

Published: 2012

Journal Articles

BCR/ABL-Mediated Myeloid Expansion Is Promoted by C/EBPβ, a Regulator of Emergency Granulopoiesis,

Yoshihiro Hayashi, MD, Hideyo Hirai, MD, PhD, Hisayuki Yao, MD, Satoshi Yoshioka, MD, Sakiko Satake, MD, Naoka Kamio, MD, Yasuo Miura, MD, PhD, Eishi Ashihara, MD, PhD, Yoshihide Fujiyama, MD, PhD, Daniel G. Tenen, Taira Maekawa, MD, PhD

Blood (2011) 118 (21): 3747.

https://doi.org/10.1182/blood.V118.21.3747.3747

Published: 2011

Journal Articles

Hypoxia-Adapted CML Cells Are More Primitive Population and Are Eradicated by Glyoxalase-1 Inhibitors.

Miki Takeuchi, MD, Shinya Kimura, MD, PhD, Junya Kuroda, MD, PhD, Eishi Ashihara, MD, PhD, Makoto Kawatani, PhD, Hiroyuki Osada, PhD, Kazuo Umezawa, PhD, Eiko Yasui, PhD, Masaya Imoto, PhD, Takashi Tsuruo, MD, PhD, Asumi Yokota, MMSc, Ruriko Tanaka, MMSc, Rina Nagao, Tatsutoshi Nakahata, M.D., Ph.D., Yoshihide Fujiyama, MD, PhD, Taira Maekawa, MD, PhD

Blood (2009) 114 (22): 2166.

https://doi.org/10.1182/blood.V114.22.2166.2166

Published: 2009

Journal Articles

Glyoxalase-I Inhibition Eliminates Hypoxia-Adapted CML Cells Resistant to Imatinib, Dasatinib, and INNO-406

Miki Takeuchi, MD, Shinya Kimura, MD, PhD, Junya Kuroda, MD, PhD, Takashi Ushiki, MD, Makoto Kawatani, PhD, Hiroyuki Osada, PhD, Kazuo Umezawa, PhD, Eiko Yasui, PhD, Masaya Imoto, PhD, Takashi Tsuruo, MD, PhD, Keiko Hodohara, MD, PhD, Tatsutoshi Nakahata, MD, PhD, Yoshihide Fujiyama, MD, PhD, Taira Maekawa, MD, PhD

Blood (2008) 112 (11): 3185.

https://doi.org/10.1182/blood.V112.11.3185.3185

Published: 2008

Journal Articles

Glyoxalase-I Is a Potential Therapeutic Target for Chronic Myelogenous Leukemia Cells That Have Acquired Drug Resistance through Adaptation to Hypoxia.

Miki Takeuchi, Junya Kuroda, Shinya Kimura, Eishi Ashihara, Kazuo Umezawa, Eiko Yasui, Makoto Kawatani, Hiroyuki Osada, Keiko Hodohara, Yoshihide Fujiyama, Taira Maekawa

Blood (2007) 110 (11): 2931.

https://doi.org/10.1182/blood.V110.11.2931.2931

Published: 2007

Journal Articles

Comparison of Imatinib, Dasatinib, Nilotinib and INNO-406 in Imatinib-Resistant Cell Lines.

Shinya Kimura, MD, Yasuyuki Deguchi, M.D., Eishi Ashihara, M.D., Tomoko Niwa, Ph.D., Keoko Hodohara, M.D., Yoshihide Fujiyama, M.D., Taira Maekawa, M.D.

Blood (2007) 110 (11): 2952.

https://doi.org/10.1182/blood.V110.11.2952.2952

Published: 2007

NARROW

C/EBPβ Is Upregulated Through STAT5 and Accelerates Exhaustion of Leukemic Stem Cells During BCR-ABL-Mediated Myeloid Expansion

BCR/ABL-Mediated Myeloid Expansion Is Promoted by C/EBPβ, a Regulator of Emergency Granulopoiesis,

Hypoxia-Adapted CML Cells Are More Primitive Population and Are Eradicated by Glyoxalase-1 Inhibitors.

Glyoxalase-I Inhibition Eliminates Hypoxia-Adapted CML Cells Resistant to Imatinib, Dasatinib, and INNO-406

Glyoxalase-I Is a Potential Therapeutic Target for Chronic Myelogenous Leukemia Cells That Have Acquired Drug Resistance through Adaptation to Hypoxia.

Comparison of Imatinib, Dasatinib, Nilotinib and INNO-406 in Imatinib-Resistant Cell Lines.

Email alerts

ASH Publications

American Society of Hematology

C/EBPβ Is Upregulated Through STAT5 and Accelerates Exhaustion of Leukemic Stem Cells During BCR-ABL-Mediated Myeloid Expansion

BCR/ABL-Mediated Myeloid Expansion Is Promoted by C/EBPβ, a Regulator of Emergency Granulopoiesis,

Hypoxia-Adapted CML Cells Are More Primitive Population and Are Eradicated by Glyoxalase-1 Inhibitors.

Glyoxalase-I Inhibition Eliminates Hypoxia-Adapted CML Cells Resistant to Imatinib, Dasatinib, and INNO-406

Glyoxalase-I Is a Potential Therapeutic Target for Chronic Myelogenous Leukemia Cells That Have Acquired Drug Resistance through Adaptation to Hypoxia.

Comparison of Imatinib, Dasatinib, Nilotinib and INNO-406 in Imatinib-Resistant Cell Lines.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only